Over the past 20 years, the care for transgender adolescents has developed throughout many countries following the "Dutch Approach" initiated in the 90's in pioneer countries as the Netherlands, United
later in adolescence or adulthood, and express a strong desire for the anatomy of the experienced gender and an aversion of the body characteristics of the birth-assigned gender (7) without a history of gender non-conformity in early childhood (4). If the distress resulting from this incongruence (so-called gender dysphoria) reaches clinical levels, the diagnosis of GD, according to current DSM 5, is applicable (Table   1 ) (1) . In pre-pubertal children, presentation varies widely, often depending on environment, some experiencing feelings such as being "trapped" in the wrong body (3) .
Persistence or desistence?
Young children who are gender non-conforming or who identify as transgender may or may not continue to identify as transgender as adolescents and adults and may follow different developmental pathways (4).
There is evidence to suggest that for the majority of them, this gender incongruence will desist and that they will identify with their birth-assigned gender by early adolescence (4, 8, 9). According to various studies, the percentage of "persisters" appears to be between 10 and 39% (10, 11). Besides, studies that have been conducted among children and adolescents have shown that GD that persists into adolescence is unlikely to subside (2, 10, 12, 13) . Therefore adolescents may be considered for medical treatment when GD persists or intensifies when puberty has started (Tanner breast or genital stage 2) (3). For those, the peripubertal and pubertal physical changes can be unbearable. In the qualitative study from Steensma et al, persisters and desisters both reported that they felt that the period between age 10 and 13 was a critical time period (10). There have been efforts to identify factors to differentiate pre-pubertal children who will persist in their transgender identity during adolescence and adulthood versus those who will desist (4) but it is currently impossible to predict persistence or desistence with certainty. Studies examining factors associated with persistence of childhood GD suggest that the likelihood of transgender identity in adolescence/adulthood may be predicted by more severe symptoms of GD and more persistent, insistent and consistent cross-gender statements and behaviors in childhood, and the tendency to assert their gender cognitively versus affectively ("I am a boy" versus "I feel like a boy") (14).
History of transgender care in children and adolescents
The beginning of transgender care for children and adolescents is marked by the seminal paper on young LGBTIQ community, came to the conclusion that trans-identity is not a psychiatric disorder but a singular construction of identity as everyone builds his/ her identity in a singular way. In the DSM 5, the condition of experiencing clinically significant distress is required to assert diagnosis of GD (1) so that a transgender person who feels well is not attributed any diagnosis. Currently, the debate is still continuing with the development of the ICD-11 (18) . Research is ongoing on the way to facilitate access to care for transgender people, to better meet their needs, but also on educational and informational programs to reduce transphobia and discriminations that are considered to contribute to dysphoria and comorbid conditions in transgender youth (19, 20) .
Epidemiological data
Few studies exist on the prevalence and incidence of GD. A recent review from Kenneth Zucker aimed to summarize actual epidemiological data among children and adolescents, based on self-identification as a transgender person or parents reporting their child as "wishing to be of opposite sex" in standardized questionnaires (21). Interestingly, from a parental point of view there seemed to be a higher prevalence of birth-assigned girls that wished to be of opposite sex than boys (21). In the pediatric population, one study in younger children was published of a random sample of 2730 students in grade 6-8 who were asked what their gender was, of whom 1.3% answered being "transgender" (22), however it remains unclear to what extent children understood the question. Similarly, high school students from New Zealand were asked the question "Do you think you are transgender" to which 1.2% answered yes. An additional 2.5%
reported not being sure about their gender and 1.7% that they did not understand the question (23). In 2016, Eisenberg et al, published a prevalence of 2.7% of transgender or gender nonconforming youth, with 3.6% of birth assigned females and 1.7% of birth assigned males considering themselves as "transgender, genderqueer, genderfluid or unsure about their gender indentity" among a random sample of 81 885 high school teenagers (24). In 2017, Becker et al, asked 940 German male and female adolescents aged 10-16 years to report their current gender experience (feminine and masculine) and expression (gender role as girl or boy). Among them, 4.1% adolescents were evaluated as variant in gender experience and 3.0% as non-conforming in expression, while 0.9% adolescents demonstrated both gender variance and non-conforming expression (25).
Aside from previous studies that estimated prevalence in the general or student population, studies from adult transgender clinics throughout the world have reported a varying clinical prevalence possibly depending on accessibility to care, society and culture. The majority of those seeking treatment were birthassigned males (between 1:3205 to 1:30000 birth-assigned males versus 1:7752 to 1:100000 birthassigned females) (21). A recent meta-analytic review by Arcelus et al, concluded that the prevalence of 'transexualism' in adult males was 1:14705 versus 1:38461 in adult females (26). In adolescents, the sex ratio also favored boys until the mid-2000s when a shift was observed to one favoring birth-assigned girls in several countries (Canada, Netherlands, Finland) (27, 28).
It is of particular interest to note that wherever a specialized transgender health care program has opened, increasing rates of children and adolescents seeking out health care have been observed, questioning whether there is a true increase in the prevalence/incidence or whether it is due to a depathologisation and destigmatisation of GD, making it easier for children/parents to seek out health care (13, 29) .
Etiological Hypotheses
Most authors consider GD to have multifactorial origins: genetic, biological, psychological and social (30, 31). Animal studies show that prenatal sex hormones do not only determine the development of the internal and external genitalia but also act on the brain in the sense of sexual differentiation (32). Recently, Beking and colleagues have shown that both prenatal and pubertal testosterone affects brain lateralization in a task-specific way in boys (33). Moreover, the increased incidence of GD in the context of Differences/Disorders of Sexual Development (DSD) has led to the hypothesis that sex steroids play a role in the etiology of GD, and that mutations in the genes encoding enzymes involved in their biosynthesis or metabolism or encoding their receptors could be implicated (31).
A neurobiological theory of the origin of GD is based on the fact that during embryogenesis, genital differentiation occurs well before sexual differentiation of the brain. Since these two processes are not synchronous, and may not require similar levels of hormonal impregnation, it is possible that in relation to variable levels of androgen secretion at these two stages, sexual organs develop towards the female phenotype while the brain differentiates towards the male phenotype, or conversely (34).
Several studies support a genetic component in GD (35, 36) . In a literature review of twin studies, including unpublished cases from specialized centers, it was possible to show a significantly higher concordance for GD among monozygotic twins than among same sex dizigotic twins (37, 38) . Familial occurrence of GD has also been described in a non-twin siblings study (39) , but in terms of absolute numbers, the likelihood for the sibling of a transgender individual to also be dysphoric is very low.
Abnormal karyotype is rarely found in transgender individuals (40) . Associations between GD and specific mutations or mean repetition numbers of specific polymorphisms in genes related to sex hormones have been investigated. The studies were conducted in transgender individuals without associated DSD, versus same-sex controls. The genes encoding the estrogen receptor alpha (ERα), the estrogen receptor beta (ERβ), the progesterone receptor (PR), and the enzymes CYP19, CYP17 and SRD5A2 were candidates. These studies, often conducted on a small number of individuals, were discordant and inconclusive (Table 3) (41, 42, 43, 44, 45, 46, 47, 48) . Recently, a study using wholegenome-and whole-exome-sequencing revealed a rare mutation in the RYR3 gene, coding for a calcium transporter, in some trangender individuals (49) .
Research in neuroimaging has also been performed. Anatomical studies seem to show that although the overall volume and the morphology of the gray and white matter remain close to birth-assigned gender (50) , very localized areas are morphologically closer to the sex concordant with gender identity (31). More recently, functional MRI studies have shown atypical activation patterns in transgender children and adolescents, either GD specific (different from both cisgender males and females) or sex-atypical (similar to their experienced gender pattern) (51). No effect of GnRH analogue (GnRHa) treatment was found on executive function (52) but effects of gender-affirming hormone therapy on the brain have been observed (53, 54) .
Regarding the psychological and environmental components, many studies have been conducted around the possible influence of parents' prenatal sex preference, but also around social reinforcement or parental emotional functioning contribution. To date, there is no evidence of an impact of the prenatal wish (55).
However, parental tolerance to cross-sex behavior and parental emotional functioning may be associated with GD but there is no evidence for specificity (55) . Moreover, what may seem an atypical parental reinforcement of feminine and masculine behavior that would encourage the child in transidentity may rather be an adequate parental adaptation to a child with GD. It is interesting to note that non-conforming gender identity is expressed in many cultures, including non-Western countries which suggests that particular cultural aspects may not be of major influence (56, 57, 58, 59 ).
Finally, a psychoanalytic hypothesis proposes to consider one's identity as constructed by a "knot" comprising several dimensions (e.g., the real body, the body image, and the symbolic dimension) (60) .
Transgender persons may be experiencing a discrepancy between these dimensions -that they can reduce by transitioning and with lots of creative non-normative possibilities so they can fulfill themselves as human beings (61) .
Guidelines for the care of transgender youth
Transgender children and adolescents should receive multidisciplinary care from mental health professionals, physicians, surgeons and ethicists, specialized in gender identity care and working together to give youth who seek gender affirming treatment from early puberty on, the chance to develop into wellfunctioning young adults.
Psychological care and Social Transitioning
According to the recommendations of the World Professional Association for Transgender Health (WPATH) (62), the Endocrine Society Clinical Practice Guidelines (3), the American Academy of Child & Adolescent Psychiatry (AACAP) (63) and the American Psychological Association (64) the mental health professional should welcome the child or adolescent and his/her family and acknowledge their concerns about gender identity, possible distress and health and well-being in general. The mental health professional offers an age-appropriate assessment for GD and any coexisting mental health concern. The clinician conducts an interview with the child or adolescent and also obtains information from the parents regarding various aspects of the child's general and psychosexual development and current functioning.
Hence, the Endocrine Society Guidelines recommend mental health clinicians should be trained in child and adolescent developmental psychology and psychopathology, competent in using the DSM and/or the ICD for diagnostic purposes, knowledgeable about the GD diagnostic criteria and able to make a distinction between GD and other conditions that may have similar presentation (e.g. body dysmorphic The mental health professional is able to refer for appropriate treatment with knowledge of the criteria for puberty blocking and gender-affirming hormone treatment in adolescents. The mental health professional carefully evaluates the adolescent's capacity to understand treatment and social conditions that can impact gender-affirming hormone therapy, diagnoses associated psychiatric conditions and makes sure that these conditions are treated appropriately, notably when they may complicate treatment, affect its outcome, or be affected by hormone use. The multidisciplinary team confirms the persistence of GD, ensures sufficient mental capacity to give informed consent to hormonal transition and further helps in decisions regarding gender-affirming surgery in older adolescents.
Puberty suppression and gender-affirming hormone therapy
The puberty suppression protocol follows the Endocrine Society guidelines (3) and is based on the "Dutch approach" designed by Profs Cohen-Kettenis and Delemarre-van de Waal (16) . The concept is to stop pubertal progression thereby attenuating the distress and anxiety linked to appearance of secondary sexual characteristics. It allows time for evaluation and may spare adolescents later gender affirming surgical procedures such as chest masculinization for transboys; ablation of adam's apple, facial surgeries for transgirls (74) , and it may prevent deepening of the voice in transgirls. GnRHa are the currently preferred treatment option and are used to suppress puberty as in precocious puberty (75) . They are long acting agonists that suppress gonadotropins secretion by a desensitization of the GnRH receptor. Treatment with GnRHa should only be considered when criteria for eligibility to puberty suppression are fulfilled (Table   4 ) most particularly once puberty has started (Tanner stage 2: initiation of breast development in birthassigned girls, testicular enlargement > 4 ml in birth-assigned boys (76)) to let adolescents experience some puberty, as a diagnostic marker, to ensure that GD is persistent (10). Efficacy and short-term safety of GnRHa puberty suppression in transgender adolescents is now well established (77). This treatment can be initiated from stage 2 to stage 4-5 of puberty, as well as in post-pubertal adolescents. One monthly intra-muscular or subcutaneous injection is usually preferable to the three-monthly injection at the initiation of treatment to ensure complete inhibition of LH and FSH secretion (75, 78) . At the onset of puberty secondary sexual characteristics may regress, or stop at later phases of pubertal development. In birth-assigned girls menses will stop and breast tissue will become atrophic. In birth-assigned boys, subsequent virilization will discontinue; most particularly GnRHa can prevent appearance of facial hair, even at late Tanner stages. One advantage is that the effects of GnRH treatment are completely reversible, thus, if the adolescent no longer wishes hormonal transitioning, treatment can be discontinued and physiological puberty will resume (79) . However, adolescent and parents must be informed of the expected side effects of treatment (transient impact on bone mineral density, transient reduced growth velocity), of the scarcity of literature concerning final adult height, peak bone mass and skeletal morphology (80) and of its impact on future surgeries (notably vaginal reconstruction in transgirls by the penile inversion skin technique, the current most commonly used technique for vaginal lining, that could be compromised by stopping penile growth) (81) and fertility preservation possibilities (61) .
In cases where puberty is well advanced, transboys may be treated by oral progestin preparation to suppress menses (82). If GnRHa are not available or in case of needle phobia, an anti-androgen can be proposed to transgirls to directly suppress androgen secretion and action (83).
If adolescents are willing to go through hormonal transitioning, gender-affirming hormones (estrogens for transgirls, androgens for transboys) can be proposed from the age of 16 years old (Table 4) . Of note, the recent Endocrine Society guidelines no longer refer to a minimal age, but rather suggest an age when the adolescent has sufficient capacity to give informed consent and weigh adequately the benefit and risk of treatments, although only minimal data support earlier use of gender-affirming hormones (3). The adolescent and his/her parents should be informed of expected effects of treatment and potential side effects notably concerning fertility. Thus, options to preserve fertility must be discussed. Initiation of gender-affirming hormones should be progressive, with a gradual dose increase and monitoring of clinical pubertal development and laboratory parameters (hormone concentrations, metabolic parameters) (3).
Treatments available in Europe
In several European countries such as the Netherlands, the United Kingdom and France GnRHa are used as initial treatment for adolescents with GD as recommended in the Endocrine Society guidelines (3, 77) .
Several formulations are available (Table 5) . However, GnRHa are not reimbursed in other countries such as Belgium and families may not be able to pay the costs out of pocket (82). Therefore some providers use anti-androgens such as cyproterone acetate to suppress endogenous sex steroids in late pubertal transgirls (from Tanner G4) and progestins in late pubertal transboys (from Tanner B4) (82, 83). Others have used spironolactone to reduce androgen-dependent hair growth in transgirls (13) . For pubertal induction oral or transdermal estradiol is preferred in transgirls whereas injections or transdermal testosterone formulations are available for transboys (Table 5 ).
Short to medium-term outcomes

Psychological
Adolescents with GD are at an increased risk of psychiatric disorders, such as anxiety disorders (21%), mood disorders (12% to 64%), risk of attempted suicide or self-aggressive behavior (5 to 53%) and of dropping out of school (13, 28, 84) . These disorders could either be comorbidities or complications of GD or might also be consequences of social impact of transidentity. In fact, a study of 218 children and adolescents (mean age = 14 yrs) conducted in a developmental perspective, highlights contexts of harassment in 49.4% of transgirls and 45.3% of transboys (85) . Recently, a clinical comparison study between four gender identity clinics across Europe showed differences in emotional and behavioral issues and peer relationships problems that were most prevalent in adolescents from the UK, followed by Switzerland, Belgium and the least by adolescents from The Netherlands. More research is needed to clarify these results and determine the factors that may contribute to them (86) .
Two longitudinal studies from the Netherlands were able to measure efficacy in terms of psychological outcomes and tolerance of GnRHa treatment (12) followed by gender-affirming hormones in adolescents (87) . The first longitudinal prospective study concerned a cohort of 70 transgender teenagers (33 transgirls and 37 transboys) eligible to receive puberty suppression treatment, that were assessed before the onset of GnRHa (T0) and shortly before the initiation of gender-affirming hormones (T1). Results demonstrated that depressive symptoms as well as behavioral and emotional issues decreased during treatment, while general performance improved significantly. However, feelings of anxiety and anger were stable during T0 and T1. In this cohort, no adolescent chose to withdraw from puberty suppression, and all went on with gender-affirming hormone therapy (12) . In the literature, a small percentage (up to 4%) of individuals who started treatment stopped because they no longer wished to undergo a gender change (13, 83) and one suicide was reported during treatment (82). The recent study by Wiepjes et al., including 6,793 transgender individuals from the Amsterdam cohort showed a percentage of only 1.9% of adolescents who stopped treatment during the phase of puberty suppression, which is also used as a prolonged diagnostic phase. However, no adolescents stopped treatment after they had started gender affirming hormone therapy (88) .
The second longitudinal study, from the same team, evaluated long-term efficiency of the global care protocol at several time points: before onset of puberty suppression (T0, mean age = 13.6 yrs), at the introduction of gender-affirming hormones (T1, mean age = 16.7 yrs), and one year after re-assignment surgery (T2, mean age = 20.7 yrs). A total of 55 young adults were evaluated (22 transwomen and 33 transmen). Focusing on their psychological functioning and their global well-being in areas such as social interactions and education or quality of life, this study demonstrates that in early adulthood, after medical and surgical gender-affirming treatment, gender dysphoria was attenuated and psychological functioning had improved. Their global well-being became equivalent to same-age young adults from the general population (87) .
Medical outcomes
No long-term studies are available yet on medical outcomes in adolescents but several studies have looked at efficacy and short to medium term side-effects/safety of puberty suppression and gender-affirming hormone treatments in adolescents. Treatment with triptorelin results in a decrease of testicular volume in most transgirls and cessation of menses in transboys and adequately suppresses gonadotropins and sex steroids (77). Medroxyprogesterone has also been used to suppress puberty in both transboys and transgirls but especially in transgirls with advanced puberty, suppression of testosterone levels is incomplete (89). Lynestrenol does not completely suppress gonadotropins either in transboys and is associated with metrorrhagia (82). Cyproterone acetate only partially suppresses testosterone but results in decreased shaving frequency in the majority of late pubertal transgirls (83). Oral oestradiol treatment induces breast development within three months in most transgirls and after three years Tanner breast stage 4-5 is attained (90) . Waist-to-hip ratio decreases during estrogen treatment and increases during testosterone treatment (80, 90) .
The following side effects have been reported during GnRHa treatment: hot flashes, fatigue, headache and mood alterations, pain from injection and sterile abcesses (3, 13) . Lynestrenol treatment is frequently associated with acne, headache, hot flashes and fatigue (82), whereas medroxyprogesterone was generally well tolerated by a small group of adolescents (89). Fatigue was common during cyproterone acetate treatment (83). Estradiol led to breast tenderness, emotionality and hunger (83) whereas testosterone resulted in acne. Height SDS decreases whereas BMI SDS is stable or increases slightly during GnRHa treatment but fat percentage increases and lean body mass percentage decreases (77, 91). Testosterone leads to an increase of BMI SDS (82) whereas estradiol does not affect BMI SDS, fat or lean body mass percentage (90) . Some studies found no change in blood pressure during testosterone or estradiol treatment (90, 92) but one study observed an increase in systolic blood pressure during testosterone treatment (93) . Transgirls have an average adult height of +1.9 SDS. High dose estradiol treatment did not seem effective for growth reduction although this treatment has only been described in a few adolescents (90) .
Bone mineral (apparent) density z-scores decrease during GnRHa treatment, especially in the lumbar spine, and increase during treatment with testosterone or estradiol (91, 94) . However, they remain lower than pre-treatment z-scores, even at age 22 years after more than 5 years of treatment with gender affirming hormones (91, 94) . One individual was reported to have normal BMD z-scores at age 35 years after treatment with GnRHa for 4.9 years followed by testosterone treatment from age 18.6 years (95).
No changes in HbA1c, insulin, glucose, or HOMA index have been found during treatment with lynestrenol, cyproterone acetate, testosterone or estradiol (82, 83, 90, 92). Mean HDL-cholesterol decreases and mean LDL-cholesterol increases during treatment with lynestrenol (82). Testosterone also induces a decrease of HDL-cholesterol (92, 93) . It is uncertain how this affects the risk of cardiovascular complications in the long term; few cardiovascular events and deaths have been reported in transgender males but available data are insufficient to draw any conclusions (96) . Total cholesterol, HDL-cholesterol and triglycerides decrease during cyproterone acetate treatment (83). Some studies found no effect of estradiol on lipid levels (83, 92) but one study reported an increase in HDL-cholesterol (93) .
Testosterone treatment causes an increase of the hematocrit but rarely (0-3%) above the normal range (82, 92). Estradiol does not affect the hematocrit in transgirls (90, 92) . Transient rises in liver enzymes were observed during cyproterone acetate treatment (83) while they remained within the normal range during testosterone and estradiol treatment (82, 90, 92) . Cyproterone acetate treatment lowers DHEAS levels, however its effects on adrenal function warrant further study (83).
Estrogen therapy is associated with an increased risk of venous thrombo-embolism and this has been reported in 0-5% of adult transwomen (96) . However, pulmonary embolism has only been described in one transgender adolescent who was overweight, smoked tabacco and used both ethinyl estradiol to stop menses and testosterone (97) .
Cyproterone acetate causes an increase of prolactin (83) and hyperprolactinemia with galactorrhea has been reported in a transgirl during high-dose ethinyl estradiol treatment (90) . Some studies found that estradiol treatment does not increase prolactin levels (90, 92) but others did find an increase although within the normal female range (93) .
Follow-up
During puberty suppression, it is thus suggested by the Endocrine Society Guideline that the adolescent be seen every 3 to 6 months for height, weight, sitting height, blood pressure and pubertal staging evaluation (3). At each visit, satisfaction with treatment, efficacy and possible side effects should be discussed (3).
Laboratory testing is suggested at least once a year to measure hormonal levels (LH, FSH, E2/T, 25 OHD). Bone mineral density using DXA should be monitored and bone age on X-ray should be proposed every 1 to 2 years if puberty was stopped at early stages (3). If puberty suppression is inadequate then adherence to therapy should be assessed and a change of dose or dose interval can be considered. In case of suspected side effects the possibilities of changing medication, stopping medication or starting gender affirming treatment need to be discussed with the adolescent. If bone mineral density shows a worrying trend then advice can be given to optimize physical activity, calcium and vitamin D intake, and an earlier start of gender affirming hormones may be considered if appropriate.
During gender affirming hormone therapy, continued evaluation of anthropometry measures and pubertal progression is suggested every 3 to 6 months (3). Prolactin, estradiol and 25 OHD levels should be checked at least once a year in transgirls on estrogens, and hemoglobin/hematocrit, lipids, testosterone and 25 OHD levels in transboys on testosterone (3). If testosterone therapy is administered intramuscularly every 2 weeks, testosterone levels should be measured midway between injections or alternatively peak and trough levels can be monitored (3) . If pubertal progression is inadequate, side effects are experienced or hormone levels are outside the target range, then a change of type or dose of medication may be considered and if abnormal laboratory results are encountered, such as erythrocytosis, temporary discontinuation of hormonal therapy may be necessary. If clinically relevant, bone mineral density using DXA and bone age on X-ray should be performed at least once every two years (3).
Transition to adult care
Transition from adolescent to adult care should be envisioned and carried out by a multidisciplinary team at the appropriate moment, including both pediatric and adult endocrinologists. These young adults should be informed of the need for long-term medical monitoring.
Hormonal therapy
Gender affirming hormones aim at attaining physiological doses (table 5), in order to avoid risks of inadequate hormone plasma levels (98, 99, 100) according to published guidelines (3). In transwomen, transdermal or oral 17beta-estradiol treatment is maintained; continuation of anti-androgenic treatment is recommended until gonadectomy, since physiological doses of estrogen alone are insufficient to inhibit testosterone secretion. There is currently no evidence regarding the hypothetic beneficial role of progestogen for breast development, and further research is needed (101).
In transmen who are adequately virilized with adult doses of testosterone, GnRHa treatment can be discontinued. If uterine bleeding occurs, progestin treatment can be prescribed until potential hysterectomy.
Follow up and long term care
Clinical evaluation is recommended every 3-6 months during the first 2 years, then once a year.
Satisfaction with hormonal therapy, quality of life and psychosocial outcomes should be fully discussed with these young adults. Clinicians should also monitor weight, blood pressure. Side effects of sex steroids and cardiovascular risk factors should be evaluated; cessation of tobacco use must be recommended. Questions concerning further surgical management will be addressed, as well as those surrounding medically assisted procreation, taking into account medical and country-specific legal contexts.
Blood testing should be performed at each visit, with evaluation of levels of prolactin, estradiol and lipids in transwomen, and testosterone, hemoglobin/hematocrit and lipids in transmen (3).
Estrogen therapy is associated with increased risk for thromboembolic disease, particularly with ethinyl oestradiol (which is no longer recommended) or when supraphysiological doses of estrogens are used (93, 102) .
When puberty is suppressed at early stages, bone mineral density should be monitored at least until the age of 25-30 years. If treatment was initiated after puberty, bone mineral density should be assessed in individuals who are not compliant with hormone therapy or who develop risks for bone loss (3).
In transwomen, prostate cancer risk is expected to be extremely low due to gland atrophy after pubertal medical castration. Long term use of high dose anti-androgens is of concern (103). A retrospective study observed a higher incidence of meningioma in a cisgender population using cyproterone acetate, especially when higher doses were used; however, further research is warranted (104) . Regarding breastscreening, guidelines are currently identical to those for cisgender females (3).
There is no existing evidence for increased risk of reproductive tract cancers in transmen. However, clinicians should inform adolescents and adults of the recommended screening if hysterectomy and oophorectomy are not considered (3) in the prevention of cervical cancer (105) or other reproductive tract cancers (106), similar to cisgender women, and of the potential long term effects of testosterone therapy on these organs (107).
In conclusion, long-term prospective studies are required, particularly for transgender individuals who will choose not to have surgery, in order to evaluate risks associated with long-term anti-androgenic treatment in transwomen, and to propose optimal gynecologic care in transmen.
Laws/Standards of care around the world
Professional organizations have consistently recognized that medical intervention is warranted and necessary for transgender adolescents (3, 4, 62, 108). Still, transgender youth face significant health disparities related to lack of access to competent care, given location, insurance coverage and cost (4), and it appears that despite these guidelines, the actual practice for GD is quite variable, and the number of adolescents receiving the recommended medical interventions compared with the number of potentially eligible individuals is quite low (109).
Controversies and many challenges persist around clinical management of gender variant children and adolescents with specific barriers that can be identified, such as: -social discomfort with treatment of GD in the pediatric population (109) , and/or moral or philosophical objections to treating transgender adolescents with hormonal therapies; -unfamiliarity with the clinical practice guidelines among mental health, primary care and endocrine providers (109, 110) , lack of confidence in their ability to provide care to this 'vulnerable population'; -limited number of centers equipped to treat GD; -disparity regarding insurance coverage for medical therapies; -high costs of puberty suppression therapy; -adolescents who do seek care at specialized centers often present at late pubertal stages, i.e. after Tanner stage 3, making pubertal suppression less effective (109); -the persistent classification of GD as a psychiatric condition, as this classification may cause a lack of awareness among adolescents, parents and providers, that GD may be treated with medical interventions in early adolescence (109); -providers may be hesitant to follow the guidelines, given limited long-term data supporting their safety and effectiveness (109) .
Nevertheless, transgender care for children and adolescents has developed and is now much more widely available. Many clinics in the world now see children and adolescents with GD and use puberty suppression protocols (7). However, some differences between countries can be identified, for instance the minimum age to initiate puberty blockers and gender affirming hormones, and the possibility for reimbursement.
A recent report provides descriptions and contact information for 35 gender programs in the US and Canada (111), like the GeMS program (6). "Gender-affirming approach to care" and medical interventions for appropriately assessed children and adolescents have become the standard of care in several states (4), with protocols adapted from existing guidelines and standards for working with transgender individuals; in Michigan, Colorado, and Massachusetts, for instance, the reported practice is to consider puberty blockers at Tanner stage 2 and gender affirming hormone treatment initiation as early as age 14 years (4).
According to the guidelines, genital surgeries are typically not recommended until the adolescent has reached legal age of majority, although chest surgery in transboys may be considered earlier. Despite the advances, many transgender adolescents report facing barriers to access competent and comprehensive medical and mental health services, including lack of access to trained providers and low rates of insurance coverage for medical therapies (108) . Legally speaking, in Anglo-American countries, it seems easier to adopt a new first name, but registration documents are not centralized (as a result, a person can be male according to one and female according to another document) (2).
In Canada, Khatchadourian et al. (13) In other countries around the world, huge disparities still persist. In Australia, recent legal developments concerning treatment for GD in children and adolescents confirm that parents are lawfully able to consent to puberty blocking medication, for children as young as 10 years old. In addition, a child who is determined by a court to be "Gillick competent" (that is who is found to possess sufficient understanding and intelligence to enable her or him to understand fully what is proposed) can consent to gender affirming hormone treatment around the age of 16 years; in other cases, gender-affirming hormone therapy has to be approved by a court (116) .
Little information was found on how the question of fertility preservation (FP) is addressed in different countries (61) . In the US and in UK (https://www.england.nhs.uk/wp-content/uploads/2017/04/genderdevelopment-service-children-adolescents.pdf), it seems that a comprehensive fertility counseling is provided in some specialized centers (4, 117, 118) but legal issues are not discussed.
In 2017, Mamoojee and Quinton reported the variation in practice in the UK, the USA, Iran, Thailand and the Netherlands, but did not mention any detail about children and adolescents, concerning disparities in legal issues, minimal age to start puberty blockers and gender-affirming hormones, or reimbursement of medical care for that specific range of age (119) . A document, the Trans Rights Europe Map & Index, published on line in May 2018, summarizes detailed country information in 25 legal categories, such as legal gender recognition, non-discrimination, health and family (https://tgeu.org/trans-rights-map-2018/).
Ethical considerations
Treatment teams providing affirmative medical transgender care to young people are inherently faced with moral dilemmas and questions. When GD persists during adolescence, the possibility of puberty suppression and gender-affirming hormone therapy has generated a debated dimension to clinical management. The beneficial effects of hormonal treatment on the adolescents' mental health, quality of life and on physical appearance that make it possible to live unobtrusively in the desired gender role are often emphasized (12, 120) . However, various ethical concerns have been raised about the risk of making the wrong (irreversible) treatment decisions, about the decision-making abilities of adolescents, and about the potential long-term adverse effects on health and on psychological and psychosexual functioning.
Interestingly, these concerns are often raised outside the scientific realm, mostly in popular media and press (for example the discussions between proponents and opponents in the Dr Phil Show on gender identity disorder -Does reparative fit? Jan 14, 2009 available at www.youtube.com/watch?v=z8lq3E85-VY, or (121, 122) ). In general, ethics has been a secondary consideration in the medical academic literature (123) . Here we will focus on three major issues: how should we categorize GD? What is a right timing of advancement of treatment? And how should we deal with long-term treatment effects, especially infertility?
In contrast to the DSM-IV, the DSM5 (30) no longer has "gender identity disorder" as a classification, but "GD". In both the to be released ICD-11 (18) and the DSM5 (30), the main challenge has been to find a balance between concerns related to the stigmatization of mental disorders and the need for diagnostic categories that facilitate access to healthcare (124) . The status of GD as a mental disorder remains the subject of heated debate (125) . In children A. A marked incongruence between one's experienced/expressed gender and assigned gender, of at least 6 months' duration, as manifested by at least six of the following criteria (one of which must be Criterion A1) : 1. A strong desire to be of the other gender or an insistence that one is the other gender (or some alternative gender different from one's assigned gender) 2. In boys (assigned gender), a strong preference for cross-dressing or simulated female attire; or in girls (assigned gender), a strong preference for wearing only typical masculine clothing and a strong resistance to the wearing of typical feminine clothing 3. A strong preference for cross-gender roles in make-believe play or fantasy play 4. A strong preference for the toys, games, or activities stereotypically used or engaged in by the other gender 5. A strong preference for playmates of the other gender 6. In boys (assigned gender), a strong rejection of typically masculine toys, games, and activities and a strong avoidance of rough-and-tumble play; or in girls (assigned gender), a strong rejection of typically feminine toys, games and activities 7. A strong dislike of one's sexual anatomy 8. A strong desire for the primary and/or secondary sex characteristics that match one's experienced gender B. The condition is associated with clinically significant distress or impairment in social, school, or other important areas of functioning Specify if: With a disorder of sex development (e.g., a congenital adrenogenital disorder such as congenital adrenal hyperplasia or androgen insensitivity syndrome)
In adolescents and adults A. A marked incongruence between one's experienced/expressed gender and assigned gender, of at least 6 months' duration, as manifested by at least two of the following criteria: 1. A marked incongruence between one's experienced/expressed gender and primary and/or secondary sex characteristics (or in young adolescents, the anticipated secondary sex characteristics) 2. A strong desire to be rid of one's primary and/or secondary sex characteristics because of a marked incongruence with one's experienced/expressed gender (or in young adolescents, a desire to prevent the development of the anticipated secondary sex characteristics) 3. A strong desire for the primary and/or secondary sex characteristics of the other gender 4. A strong desire to be of the other gender (or some alternative gender different from one's assigned gender) 5. A strong desire to be treated as the other gender (or some alternative gender different from one's assigned gender) 6. A strong conviction that one has the typical feelings and reactions of the other gender (or some alternative gender different from one's assigned gender) Birth-assigned gender: the gender that is assumed on the basis of the phenotype / physical sex characteristics present at birth (110) Gender identity is a person's own perception of their gender, that is their internal feeling of being, for example, boy or girl, male or female, a-gender, non-binary, trans-gender, gender queer....(7). Unlike gender expression (see below), gender identity is not visible to others. Gender role: attitudes, feelings and behaviors that a society, in a given historical period, in a given culture, associates with a person's birth-assigned gender; as so, it's a social construct and varies by place and time period (e.g., men: aggressive, strong, dominant, emotionally reserved; women: nurturing, dependent, passive…) Gender expression: how gender identity is communicated to others (e.g one's name, gender pronoun, style of dresses…), that is, external manifestations of gender. Gender expression is all about how you demonstrate your gender through the ways you act, dress, behave, and interact, whether that is intentional or unintended. Gender expression is interpreted by others perceiving your gender based on traditional gender roles (e.g., men wear pants, women wear dresses). As so, gender role or gender expression describes how a person presents themselves as masculine or feminine in the context of societal expectations.
Gender attribution describes the process whereby other observers view a person as masculine or feminine.
Gender variance refers to gender expression and/or identity inconsistent with prevailing societal expectations and norms (6).
Transgender is an umbrella term used to identify individuals whose gender identity does not conform to conventional gender roles of either male or female (13); not all trans-people necessarily experience a complete cross-gender identity, want hormone therapy as well as surgery, and want to live as the other gender permanently or completely (2). Transgirl or transwoman or transgender female or male-to-female or MtF: term used to identify a birthassigned male whose gender identity is female. Transboy or transman or transgender male or female-to-male or FtM: term used to identify a birthassigned female whose gender identity is male. Gender dysphoria: internal distress experienced due to the discordance between gender identity and birthassigned gender Cisgender: when your birth-assigned gender aligns with how you identify (term introduced to describe individuals who have a gender identity congruent with or the same as their birth-assigned gender). Transitioning: Process by which an individual begins living in their affirmed gender role (may or may not include hormonal and/or surgical treatment). E.g, social transition: presenting in social settings as the affirmed gender Gender identity, gender expression, birth-assigned gender, and sexual orientation are independent of one another. Treatment by GnRH analogs for pubertal suppression can be proposed if: -Criteria for Gender Dysphoria have been confirmed by a qualified mental health professional, and no co-existing morbidity prevents initiation of therapy -Pubertal development has initiated (≥ Tanner stage 2), and there are no contraindication to GnRH agonist treatment -The adolescent and the parents have been informed of the expected effects of treatment, of its potential side effects, of its impact on future surgeries and the fertility preservation possibilities. -The adolescent has demonstrated capacity to fully understand the treatment protocol and its implications and has given his/her informed consent. Parents must also be involved in supporting the adolescent, and give their informed consent when the legal age for medical consent is not reached.
-Treatment is proposed by a multidisciplinary team qualified in transgender care
Treatment by androgens/estrogens for gender-affirming pubertal development can be proposed if:
-The above criteria are fulfilled -The adolescent and parents have been informed of the expected effects of treatment, of its potential side effects, and its consequences on fertility. Fertility preservation options have been discussed. -The adolescent as reached an age where he/she is considered in sufficient mental capacity to evaluate benefits and risks of this partly irreversible treatment (usually by age 16 years) -Adolescent and parents (when the legal age for medical consent is not reached) have given their informed consent -Treatment is proposed by a multidisciplinary team qualified in transgender care
